MONARCS
Monoclonal Anti-TNF: A Randomized Controlled Sepsis. A clinical trial, conducted in 157 US sites, which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the patients using Il-6, a cytokine marker for severity of inflammation
Results Treated patients had a 36% mortality; untreated patients, 33%Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
MONARCS
Immunology A clinical trial–Monoclonal Anti-TNF: a Randomized Controlled Sepsis trial which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the Pts using Il-6, a cytokine marker for severity of inflammation; treated Pts had a 36% mortality; untreated Pts, 33%. See Afelimomab, Sepsis. McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive
Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the
MONARCS trial.
72 (RAMSES study) controlled hours Severe sepsis 2634 Baseline to 72 hours secondary to documented infection (
MONARCS trial) Ref.
Copyright © 2003-2025 Farlex, Inc
Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.